Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: A model approach

European Journal of Health Economics

Volumn 11, Issue 1, 2010, Pages 15-25

  Jürgensen, Jan Steffen ^a   Arns, Wolfgang ^b   Ha, Bastian ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Kliniken der Stadt Koln   (Germany)

^c IQVIA   (United States)

Author keywords

Cost effectiveness; Immunosuppression; Markov model; Renal transplant; Sirolimus

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DIALYSIS; DRUG COST; GERMANY; GRAFT FAILURE; HEALTH INSURANCE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; NEOPLASM; PRIORITY JOURNAL; RETRANSPLANTATION; SENSITIVITY ANALYSIS; SIMULATION; WOUND HEALING IMPAIRMENT;

COST-BENEFIT ANALYSIS; CYCLOSPORINE; GERMANY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, STATISTICAL; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 76649093278     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0148-3     Document Type: Article

References (40)

1. A Grassmann S Gioberge S Moeller G Brown 2006 End-stage renal disease: global demographics in 2005 and observed trends Artif. Organs 30 895 897 10.1111/j.1525-1594.2006.00321.x 10.1111/j.1525-1594.2006.00321.x (Pubitemid 44915577)
2. NA Meguid El AK Bello 2005 Chronic kidney disease: the global challenge Lancet 365 331 340
3. W Fiebiger C Mitterbauer R Oberbauer 2004 Health-related quality of life outcomes after kidney transplantation Health Qual. Life Out. 2 2 10.1186/1477-7525-2-2 10.1186/1477-7525-2-2 (Pubitemid 39112027)
4. JT Joseph LS Baines MC Morris RM Jindal 2003 Quality of life after kidney and pancreas transplantation: a review Am. J. Kidney Dis. 42 431 445 10.1016/S0272-6386(03)00740-6 10.1016/S0272-6386(03)00740-6 (Pubitemid 37048119)
5. Nagel, E., Niechzial, M.: Bewertung chirurgischer Therapien. Angemessenheit - Notwendigkeit - Zweckmäigkeit, pp. 113-128. Springer, Berlin (1999)
6. WC Winkelmayer MC Weinstein MA Mittleman RJ Glynn JS Pliskin 2002 Health economic evaluations: the special case of end-stage renal disease treatment Med. Decis. Making 22 417 430 10.1177/027298902320556118 (Pubitemid 35050651)
7. RA Wolfe VB Ashby EL Milford, et al. 1999 Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant N. Engl. J. Med. 341 1725 1730 10.1056/NEJM199912023412303 10.1056/NEJM199912023412303
8. R Woodroffe GL Yao C Meads, et al. 2005 Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study Health Technol. Assess. 9 1 4
9. Frei, U., Schober-Halstenberg, H.J.: Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2005/2006. http://www.quasi-niere.de/download/berichte/de/QuaSi-Niere-Bericht- 2005-2006.pdf (2006)
10. Nebel, M.: Kosten der Nierenersatztherapie. In: Hoerl, W.H., Wanner, C. (eds.) Dialyseverfahren in Theorie und Praxis, pp. 619-629. Thieme Verlag, Stuttgart (2003)
11. I Griebsch 2005 Immunosuppressive treatment following kidney transplantation Pharm. Unserer Zeit 34 322 330 10.1002/pauz.200500132 10.1002/pauz.200500132 (Pubitemid 40991512)
12. G Knoll 2008 Trends in kidney transplantation over the past decade Drugs 68 Suppl 1 3 10 10.2165/00003495-200868001-00002 10.2165/00003495-200868001- 00002 (Pubitemid 351601432)
13. EG Hagenmeyer B Haussler E Hempel, et al. 2004 Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications Transplantation 77 1545 1550 10.1097/01.TP.0000121763.44137.FA 10.1097/01.TP.0000121763.44137.FA (Pubitemid 38703035)
14. FA Sonnenberg JR Beck 1993 Markov models in medical decision making: a practical guide Med. Decis. Making 13 322 338 10.1177/0272989X9301300409 10.1177/0272989X9301300409 (Pubitemid 24013155)
15. AC Webster VW Lee JR Chapman JC Craig 2006 Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials Transplantation 81 1234 1248 10.1097/01.tp.0000219703.39149.85 10.1097/01.tp.0000219703.39149.85 (Pubitemid 43804540)
16. P McEwan K Baboolal P Conway CJ Currie 2005 Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom Clin. Ther. 27 1834 1846 10.1016/j.clinthera.2005.11.002 10.1016/j.clinthera.2005.11.002 (Pubitemid 41815235)
17. HM Kauffman 2006 Malignancies in organ transplant recipients J. Surg. Oncol. 94 431 433 10.1002/jso.20579 10.1002/jso.20579 (Pubitemid 44465349)
18. F Vincenti 2002 What's in the pipeline? New immunosuppressive drugs in transplantation Am. J. Transplant. 2 898 903 10.1034/j.1600-6143.2002.21005.x 10.1034/j.1600-6143.2002.21005.x (Pubitemid 36330218)
19. Institut für das Entgeltsystem im Krankenhaus gGmbH (InEK). Fallpauschalen-Katalog 2007. http://www.g-drg.de/cms/index.php/inek-site-de/g- drg-system-2007/fallpauschalen-katalog/fallpauschalen-katalog-2007 (2007)
20. Institut für das Entgeltsystem im Krankenhaus gGmbH (InEK). Abschlussbericht. Weiterentwicklung des G-DRG-Systems für das Jahr 2007. Klassifikation, Katalog und Bewertungsrelation. http://www.g-drg.de/cms/index. php/inek-site-de/g-drg-system-2007/abschlussbericht-zur-weiterentwicklung-des- drg-systems-und-report-browser/abschlussbericht-zur-weiterentwicklung-des-drg- systems-fuer-2007 (2007)
21. Woodroffe, R., Yao, G.L., Meads, C., et al.: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol. Assess. 2005, 194 (2005)
22. ifap Service-Institut für Ärzte und Apotheker GmbH. IfAP Index Praxis (Status:10/2007). 1-10-2007
23. Y Vanrenterghem C Ponticelli JM Morales, et al. 2003 Prevalence and management of anemia in renal transplant recipients: a European survey Am. J. Transplant. 3 835 845 10.1034/j.1600-6143.2003.00133.x 10.1034/j.1600-6143.2003. 00133.x (Pubitemid 36827905)
24. von der Schulenburg, J.M., Greiner, W., Jost, F., et al.: German recommendations on health economic evaluation - third and updated version of the Hanover Consensus. Gesundh. ökon. Qual. manag. 12, 285-290 (2007)
25. Evans, M., Hastings, N., Peacock, B.: Triangular distribution. In: Statistical distributions, pp. 187-188. Wiley, New York (2000)
26. M Naderi J Aslani M Hashemi S Assari M Amini V Pourfarziani 2007 Prolonged rehospitalizations following renal transplantation: causes, risk factors, and outcomes Transplant. Proc. 39 978 980 10.1016/j.transproceed.2007. 03.081 10.1016/j.transproceed.2007.03.081 (Pubitemid 46764907)
27. Zeller, W.J.: Immuntherapeutika und Zytostatika. In: Schwabe, U., Paffrath, D. (eds.) Arzneiverordnungs-Report 2006. Aktuelle Daten, Kosten, Trends und Kommentare, pp. 664-677. Springer-Verlag, Berlin (2007)
28. W Kleophas H Reichel 2007 International study of health care organization and financing: development of renal replacement therapy in Germany Int. J. Health Care Finan. Econ. 7 185 200 10.1007/s10754-007-9020-0 10.1007/s10754-007-9020-0
29. M Barbieri M Drummond R Willke J Chancellor B Jolain A Towse 2005 Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability Value Health 8 10 23 10.1111/j.1524-4733.2005.03070.x 10.1111/j.1524-4733.2005.03070.x (Pubitemid 40293637)
30. A Briggs A Gray 2000 Using cost effectiveness information BMJ 320 246 10.1136/bmj.320.7229.246 10.1136/bmj.320.7229.246
31. P McEwan S Dixon K Baboolal P Conway CJ Currie 2006 Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK Pharmacoeconomics 24 67 79 10.2165/00019053-200624010-00006 10.2165/00019053-200624010-00006 (Pubitemid 43197232)
32. G Russ N Jamieson R Oberbauer, et al. 2007 Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine Transpl. Int. 20 875 883 10.1111/j.1432-2277.2007. 00547.x 10.1111/j.1432-2277.2007.00547.x (Pubitemid 47390202)
33. H Ekberg H Tedesco-Silva A Demirbas, et al. 2007 Reduced exposure to calcineurin inhibitors in renal transplantation N. Engl. J. Med. 357 2562 2575 10.1056/NEJMoa067411 10.1056/NEJMoa067411 (Pubitemid 350294223)
34. BJ Nankivell RJ Borrows CL Fung PJ O'Connell JR Chapman RD Allen 2004 Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology Transplantation 78 557 565 10.1097/01.TP.0000128636.70499.6E 10.1097/01.TP.0000128636.70499.6E (Pubitemid 39097102)
35. Z Philips L Bojke M Sculpher K Claxton S Golder 2006 Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment Pharmacoeconomics 24 355 371 10.2165/00019053-200624040-00006 10.2165/00019053-200624040-00006
36. Frei, U., Schober-Halstenberg, H.J.: Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2004/2005. http://www.quasi-niere.de/download/berichte/de/QuaSi-Niere-Bericht- 2004-2005.pdf (2005)
37. Kupsch, S., Kern, A.O., Hallauer, J.F.: Versorgung von Patienten mit Nierenersatztherapie in Deutschland - Epidemiologische, medizinische und ökonomische Aspekte von Dialyse und Transplantation, pp. 161-171. Kiel Institut fuer Gesundheits-System-Forschung, Kiel (1998)
38. Kalble, T., Lucan, M., Nicita, G., Sells, R., Burgos Revilla, F.J., Wiesel, M.: EAU guidelines on renal transplantation. http://www.uroweb.org/ fileadmin/user-upload/Guidelines/23%20Renal%20Transplant.pdf (2004)
39. I Koster L von Ferber P Ihle I Schubert H Hauner 2006 The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM study Diabetologia 49 1498 1504 10.1007/s00125-006-0277-5 10.1007/s00125-006-0277-5 (Pubitemid 43848085)
40. JJ Augustine TC Knauss JA Schulak KA Bodziak C Siegel DE Hricik 2004 Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients Am. J. Transplant. 4 2001 2006 10.1111/j.1600-6143. 2004.00612.x 10.1111/j.1600-6143.2004.00612.x (Pubitemid 39611627)